Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
2.
Klin Med (Mosk) ; 86(10): 47-52, 2008.
Article in Russian | MEDLINE | ID: mdl-19069460

ABSTRACT

The aim of the study was to assess the expediency of prescription and efficiency of bismuth tri-potassium di-citrate in different therapeutic schemes for the management of irritable bowel syndrome (IBS) dominated by diarrhea. The open prospective study of de-nol efficacy and safety included 30 patients with this disorder allocated to 2 groups. Patients of the main group (n=20) were given 120 mg of de-nol thrice daily in combination with meteospasmyl (a spasmolytic and antifoaming agent). Control patients (n=10) received aluminium phosphate with meteospasmyl (1 capsule thrice daily). Duration of the treatment was 3 weeks. Therapeutic efficiency was assessed from the dynamics of abdominal pain syndrome, stool frequency, properties of faeces, results of their microscopic and microbiological studies, lactulose breath hydrogen test, rectoromanoscopy with rectal mucosal biopsy, and hepatic biochemical test. Before the study, all patients had abdominal pain, diarrhea, meteorism, altered composition of fecal bacteria, their excessive growth in the intestines, and morphological signs of chronic inflammation. Bacterial activity was recorded in 80 and 40% of the patients of the respective groups. By the end of therapy, abdominal pain was eliminated in 90 and 60%, meteorism was absent in 80 and 40%, diarrhea in 75 and 50%, excessive bacterial growth in small intestine in 75 and 30%, changes of fecal microflora persisted in 20 and 70%, histological signs of active mucosal inflammation remained in 40 and 85.7% of the patients of the main and control groups respectively. It is concluded that all patients with irritable bowel syndrome and diarrhea show altered composition of intestinal microflora, morphological signs of moderate chronic inflammation of intestinal mucosa. Most of them have apparent bacterial activity. Treatment with de-nol and spasmolytics for 3 weeks effectively eliminated clinical manifestations of the disease, restored normal composition of intestinal microflora, normalized faeces properties, and resolved active inflammation.


Subject(s)
Anti-Infective Agents/therapeutic use , Diarrhea/drug therapy , Irritable Bowel Syndrome/drug therapy , Organometallic Compounds/therapeutic use , Adolescent , Adult , Anti-Infective Agents/administration & dosage , Bismuth , Diarrhea/diagnosis , Diarrhea/etiology , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Irritable Bowel Syndrome/complications , Irritable Bowel Syndrome/diagnosis , Male , Middle Aged , Organometallic Compounds/administration & dosage , Propylamines/administration & dosage , Propylamines/therapeutic use , Prospective Studies , Treatment Outcome , Young Adult
5.
Ter Arkh ; 78(2): 21-6, 2006.
Article in Russian | MEDLINE | ID: mdl-16613091

ABSTRACT

AIM: To study effects of the probiotic bifiform on efficacy of Helicobacter pylori (HP) eradication in patients with chronic gastritis and ulcer disease. MATERIAL AND METHODS: A total of 98 patients with verified HP infection were divided into two groups. The study group received a week three-component anti-HP therapy+a probiotic. The control group received the same treatment without the probiotic. All the patients were tested for HP before the treatment and one month after the end of the treatment. Cell composition of duodenal mucosa (DM), tissue proinflammatory cytokines, secretory immunoglobulin A (sIgA) in coprofiltrates, serum IgA, IgM, IgG, phagocytic parameters and copromicrobiology were studied. RESULTS: HP eradication rate in the study group was higher than in the control group (89.1 vs 63.5, respectively, p < 0.05). After the treatment, patients of the study group had lower rates of side effects, impaired intestinal biocenosis, tissue cytokines levels but higher concentration of plasmatic cells in CO and cIgA in coprofiltrates. CONCLUSION: The addition of probiotic bifiform to the standard three-component antihelicobacter scheme of the treatment raises its efficacy and is promising treatment of HP. Mechanisms of a potentiating action of the probiotic are related to enhancement of antibacterial activity of local immune reactions.


Subject(s)
Bifidobacterium , Helicobacter Infections/drug therapy , Helicobacter pylori , Probiotics/therapeutic use , Adolescent , Adult , Anti-Bacterial Agents/therapeutic use , Antibodies, Bacterial/immunology , Female , Follow-Up Studies , Gastric Mucosa/microbiology , Gastritis/drug therapy , Gastritis/microbiology , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/immunology , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Stomach Ulcer/drug therapy , Stomach Ulcer/microbiology , Treatment Outcome
6.
Eksp Klin Gastroenterol ; (3): 21-5, 116, 2003.
Article in Russian | MEDLINE | ID: mdl-14556541

ABSTRACT

The purpose of this study is to assess the efficiency of the anti-ulcer therapy taking into account the economic aspects of treatment. We have examined 708 HP-positive(+) patients with stomach ulcers (SU) and duodenal ulcers (DU). Various schemes of anti-helicobacter and anti-secretory therapy were administered to them. Positive dynamics of some clinical data (local palpatory tenderness and abdominal wall resistance) and gastritis (gastroduodenitis) activity was discovered in all groups of patients. The cost of the treatment was determined with the help of marketing studies by taking the lowest price of drugs. There were no statistically reliable differences found groups of traditional treatment regimens by both results of HP eradication and the cost of eradicative and anti-secretory therapy. All drugs under study are highly effective for rapid relief of symptoms at an exacerbation of stomach ulcer associated with HP as well as the decrease of gastritis (gastroduodenitis) activity. It is possible to recommend them for both eradicative therapy and prolonged treatment.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Ulcer/drug therapy , Adult , Aged , Aged, 80 and over , Anti-Ulcer Agents/economics , Cost-Benefit Analysis , Duodenal Ulcer/drug therapy , Female , Gastritis/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Stomach Ulcer/drug therapy , Time Factors , Treatment Outcome
8.
Antibiot Khimioter ; 45(6): 33-9, 2000.
Article in Russian | MEDLINE | ID: mdl-10904808

ABSTRACT

Within 1968-1997 the authors studied the steps of introduction of the achievements of the medical science, technology and pharmacology to therapy of exacerbations and complications of peptic ulcer (PU). The scientific and practical value of endoscopic, histological, biochemical and bacteriological examinations in the improvement of the methods of pharmacotherapy of exacerbations and complications of PU was shown. Three phases of the PU development were indicated by the clinical signs and results of esophagogastroduodenoscopy, target biopsy and histological examinations. These data and available scientific achievements were assumed as a basis for the design of optimal drug combinations and their introduction to the medical practice. The use of such combinations made it possible to prevent relapses and life-threatening complications of the disease in the overwhelming majority of the patients. The best results of the pharmacotherapy were recorded in the years (1988-1997) when the drug combinations began to be used. The combinations provided eradication of Helicobacter pylori in the gastroduodenal mucosa and it was proved that in all the patients with PU and the relapsing lesions in the duodenum and in the overwhelming majority of the patients with gastric ulcer the disease developed at the background of chronic active gastroduodenitis associated with H.pylori. The success of the pharmacotherapy in the patients with PU was due to the use of the rational combinations of antibacterial and antisecretory agents.


Subject(s)
Ambulatory Care/standards , Drug Therapy/standards , Outpatient Clinics, Hospital , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Drug Therapy, Combination , Helicobacter Infections/drug therapy , Humans , Moscow , Peptic Ulcer/drug therapy , Time Factors
9.
Ter Arkh ; 67(2): 26-9, 1995.
Article in Russian | MEDLINE | ID: mdl-7725253

ABSTRACT

453 patients with ulcer located in the duodenal bulb and pyloric part of the stomach in the presence of Helicobacter pylori were examined before and followed up after hospital treatment of the ulcer. The authors findings support the importance of maintenance with current antisecretory drugs and on-demand therapy as well as of combined antibacterial therapy against Helicobacter pylori. Adequate chemotherapy in the ulcer exacerbation was able to reduce the number of recurrences and complications.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Helicobacter Infections/complications , Helicobacter Infections/drug therapy , Helicobacter pylori , Peptic Ulcer/complications , Peptic Ulcer/drug therapy , Adolescent , Adult , Drug Evaluation , Drug Therapy, Combination , Female , Helicobacter Infections/prevention & control , Humans , Male , Middle Aged , Peptic Ulcer/prevention & control , Recurrence
10.
Ter Arkh ; 64(1): 71-5, 1992.
Article in Russian | MEDLINE | ID: mdl-1523569

ABSTRACT

The authors provide the results of the treatment and prophylaxis of peptic ulcer (PU) patients followed up by the polyclinic for 14 years. On a large factual material they estimate the efficacy of PU patients treatment with the use of drugs belonging to different groups, including drugs that exert antisecretory, cytoprotective and antibacterial effects. During the follow-up period, the number of patients with medium-grave and grave PU decreased whereas that of patients with mild disease and no relapses rose for 4-5 years and over (from 4.8% in 1972 to 39.6% in 1989). It has been established that the efficacy of rehabilitation measures for PU is determined by a lot of factors, first of all by adequate drug therapy with the use of the novel pharmacological preparations: selective blockers of histamine H2-receptors (ranitidine, famotidine), colloidal bismuth subcitrate (de-nol) that exert a cytoprotective and antibacterial action on Helicobacter pylori. The combination of the indicated remedies with antibacterial drugs (trichopol, oxacillin, furazolidon) for the treatment of PU relapses and their prevention is based.


Subject(s)
Ambulatory Care , Duodenal Ulcer/rehabilitation , Stomach Ulcer/rehabilitation , Biopsy , Combined Modality Therapy , Duodenal Ulcer/pathology , Duodenum/pathology , Endoscopy, Digestive System , Esophagus/pathology , Gastric Mucosa/pathology , Humans , Intestinal Mucosa/pathology , Mucous Membrane/pathology , Recurrence , Remission Induction , Stomach Ulcer/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...